search
Back to results

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Primary Purpose

Hepatitis B, Chronic

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
IMC-I109V-101 Single Ascending Dose
IMC-I109V-101 Multiple Ascending Doses
Sponsored by
Immunocore Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatitis B, Chronic focused on measuring HBeAg negative, HLA-A*02;01 Positive, T Cell Receptor (TCR)

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: ≥ 18 years old at time of informed consent HLA-A*02:01 positive Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b. Historical liver biopsy consistent with CHB infection. Have been receiving entecavir and/or tenofovir (including tenofovir alafenamide) for ≥12months prior to screening and are willing to continue. HBV DNA negative at screening No history of liver cirrhosis AND prior assessment of fibrosis demonstrating non-cirrhotic status at screening Participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of the study intervention or longer if required by local regulations Exclusion Criteria: Pregnant or lactating persons Known co-infection with any of the following: HIV, Hepatitis C virus, OR Hepatitis D virus Changes in HBeAg status within 3 months prior to the screening visit Known HBV genotype A Gilbert's syndrome Any known pre-existing medical or psychiatric condition that could interfere with the participant's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to: Immunologically-mediated disease, e.g. inflammatory bowel disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, scleroderma, or sarcoidosis within 5 years of the screening visit. Current or history of any clinically significant cardiac abnormalities/dysfunction, e.g. congestive heart failure, myocardial infarction ≤6 months prior to the screening visit, pulmonary hypertension, complex congenital heart disease, significant arrhythmia, or active cardiac ischemia. Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding esophageal varices, hepatorenal syndrome, or hepatic encephalopathy. Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia Evidence of active or suspected malignancy, or a history of malignancy ≤3 years prior to the screening visit (except adequately treated carcinoma in situ, basal cell carcinoma of the skin, or stage 0 HCC that has been treated). NOTE: Participants under evaluation for malignancy are not eligible Receiving or planning to receive systemic immunosuppressive medications during the study or ≤ 2 months prior to Day1, including but not limited to prednisone >10 mg/day (or equivalent), methotrexate, cyclosporine, or interferon. NOTE: Local steroid therapy is allowed (eg, inhaled, otic, ophthalmic, or intra-articular medications) Use of any live vaccines against infectious diseases within 4 weeks of the first planned administration of study intervention or use of any non-live vaccines against infectious diseases within 2 weeks of the first planned administration of study intervention. Treatment with any investigational drug or enrollment in any other clinical study ≤ 3 months prior to Day1, or at any time during participation in the study. Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the screening visit, except for those participants monitored in an opioid substitution maintenance program.

Sites / Locations

  • University of Southern California Keck School of Medicine
  • University Hospitals Cleveland Medical Center Case Western Reserve
  • Linear Clinical Research
  • St. Vincent's HospitalRecruiting
  • Scienta Clinical Research
  • Universitair Ziekenhuis Antwerp
  • Aarhus University
  • Queen Mary HospitalRecruiting
  • Pusan National University HospitalRecruiting
  • Asan Medical Center
  • Gangnam Severance Hospital-Yonsei University Health SystemRecruiting
  • SMG-SNU Boramae Medical CenterRecruiting
  • Auckland Clinical Studies
  • ID Clinic Myslowice
  • ARENSIA Exploratory Medicine Research ClinicRecruiting
  • Hospital Universitari Vall d'Hebron de BarcelonaRecruiting
  • Hospital Ramón and CajalRecruiting
  • Hospital Universitario Puerta de Hierro Majadahonda
  • Hospital Universitario Virgen de la Victoria
  • Kaohsiung Medical University Chung-Ho
  • Taipei Veterans General Hospital
  • Guy's Hospital, Dept. of Infectious Disease
  • Chelsea and Westminster Hospital, Research and Development, Clinical Trials Facility
  • Nottingham University Hospitals NHS Trust Biomedical Research CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part 1: Single Ascending Dose (SAD)

Part 2: Multiple Ascending Doses (MAD)

Arm Description

SAD will be approximately 10 weeks for each participant, comprising a maximum 42-day screening period, a 1-day treatment period involving a single administration of IMC-I109V and a 28-day follow-up period, for a total of 8 visits. Visits will take place on Day -1 and Days 1, 2, 3, 8, 15, 22, and 29. Follow-up may be extended in participants who achieve a decrease in HBsAg of > 0.5 log10 IU/mL at Day 29.

MAD will be approximately 54 weeks for each participant, comprising a maximum 42-day screening period, a 24-week treatment period involving weekly administration of IMC-I109V, and a 24-week follow-up period, with a total of 29 visits. Visits will take place on Day -1 and Days 1, 3 and 8, Weeks 3 (Day 15) through 24, Weeks 28, 36, 48 and 49. Participants who have achieved HBsAg <100 IU/mL at end of Week 24 may be considered for further study treatments of up to Week 48 and follow-up visits every 12 weeks to Week 72. Treatment will be discontinued at Week 16 in participants who have not shown evidence of a response to IMC-I109V, in order to minimize unnecessary drug exposure in participants who are unlikely to achieve reductions in viral biomarkers with further doses.

Outcomes

Primary Outcome Measures

Incidence and severity of treatment-emergent adverse events (TEAEs)
Incidence of serious adverse events (SAEs)
Incidence of adverse events (AEs) leading to treatment discontinuation
Incidence of dose-limiting toxicities (DLTs)
Changes in Vital Signs
Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities.
Changes in electrocardiogram
QTcF interval absolute values and changes from baseline.
Change in safety laboratory parameters
Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities.

Secondary Outcome Measures

Maximum drug concentration (Cmax)
Area under the plasma concentration versus time curve (AUC)
The time to reach maximum drug concentration (Tmax)
The elimination half-life (t1/2)
Incidence of anti-IMC-109V antibody formations
Antiviral Effects: HBsAg change from baseline
Antiviral Effects: HBcrAg change from baseline
Antiviral Effects: HBV RNA change from baseline
Antiviral Effects: HBsAb change from baseline

Full Information

First Posted
April 12, 2023
Last Updated
September 26, 2023
Sponsor
Immunocore Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05867056
Brief Title
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
Official Title
An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Participants With Chronic HBV Infection Who Are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 12, 2020 (Actual)
Primary Completion Date
September 10, 2024 (Anticipated)
Study Completion Date
December 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Immunocore Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB). This is the first in-human study of IMC-I109V in persons with CHB.
Detailed Description
IMC-I109V-101 is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-I109V in single and multiple dose regimens and to provide a preliminary assessment of antiviral activity, when administered to virally suppressed hepatitis B e-antigen (HBeAg)-negative participants receiving long-term NA therapy. The aim of this study is to identify safe, tolerable, and clinically active dose (CAD) regimens of IMC-I109V for further clinical development. The IMC-I109V study is divided into 2 main parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis B, Chronic
Keywords
HBeAg negative, HLA-A*02;01 Positive, T Cell Receptor (TCR)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Participants will receive a single dose of IMC-I109V-101 in Part 1 (SAD) and 24 weekly doses in Part 2 (MAD).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Single Ascending Dose (SAD)
Arm Type
Experimental
Arm Description
SAD will be approximately 10 weeks for each participant, comprising a maximum 42-day screening period, a 1-day treatment period involving a single administration of IMC-I109V and a 28-day follow-up period, for a total of 8 visits. Visits will take place on Day -1 and Days 1, 2, 3, 8, 15, 22, and 29. Follow-up may be extended in participants who achieve a decrease in HBsAg of > 0.5 log10 IU/mL at Day 29.
Arm Title
Part 2: Multiple Ascending Doses (MAD)
Arm Type
Experimental
Arm Description
MAD will be approximately 54 weeks for each participant, comprising a maximum 42-day screening period, a 24-week treatment period involving weekly administration of IMC-I109V, and a 24-week follow-up period, with a total of 29 visits. Visits will take place on Day -1 and Days 1, 3 and 8, Weeks 3 (Day 15) through 24, Weeks 28, 36, 48 and 49. Participants who have achieved HBsAg <100 IU/mL at end of Week 24 may be considered for further study treatments of up to Week 48 and follow-up visits every 12 weeks to Week 72. Treatment will be discontinued at Week 16 in participants who have not shown evidence of a response to IMC-I109V, in order to minimize unnecessary drug exposure in participants who are unlikely to achieve reductions in viral biomarkers with further doses.
Intervention Type
Drug
Intervention Name(s)
IMC-I109V-101 Single Ascending Dose
Other Intervention Name(s)
SAD
Intervention Description
Single dose administration of IMC-I109V-101
Intervention Type
Drug
Intervention Name(s)
IMC-I109V-101 Multiple Ascending Doses
Other Intervention Name(s)
MAD
Intervention Description
Multidose administration of IMC-I109V-101
Primary Outcome Measure Information:
Title
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time Frame
Up to 280 days post-dose
Title
Incidence of serious adverse events (SAEs)
Time Frame
Up to 280 days post-dose
Title
Incidence of adverse events (AEs) leading to treatment discontinuation
Time Frame
Up to 280 days post-dose
Title
Incidence of dose-limiting toxicities (DLTs)
Time Frame
Up to 280 days post-dose
Title
Changes in Vital Signs
Description
Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities.
Time Frame
Up to 280 days post-dose
Title
Changes in electrocardiogram
Description
QTcF interval absolute values and changes from baseline.
Time Frame
Up to 280 days post-dose
Title
Change in safety laboratory parameters
Description
Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities.
Time Frame
Up to 280 days post-dose
Secondary Outcome Measure Information:
Title
Maximum drug concentration (Cmax)
Time Frame
Up to 162 days post-dose
Title
Area under the plasma concentration versus time curve (AUC)
Time Frame
Up to 280 days post-dose
Title
The time to reach maximum drug concentration (Tmax)
Time Frame
Up to 280 days post-dose
Title
The elimination half-life (t1/2)
Time Frame
Up to 280 days post-dose
Title
Incidence of anti-IMC-109V antibody formations
Time Frame
Up to 280 days post-dose
Title
Antiviral Effects: HBsAg change from baseline
Time Frame
Up to 280 days post-dose
Title
Antiviral Effects: HBcrAg change from baseline
Time Frame
Up to 280 days post-dose
Title
Antiviral Effects: HBV RNA change from baseline
Time Frame
Up to 280 days post-dose
Title
Antiviral Effects: HBsAb change from baseline
Time Frame
Up to 280 days post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥ 18 years old at time of informed consent HLA-A*02:01 positive Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b. Historical liver biopsy consistent with CHB infection. Have been receiving entecavir and/or tenofovir (including tenofovir alafenamide) for ≥12months prior to screening and are willing to continue. HBV DNA negative at screening No history of liver cirrhosis AND prior assessment of fibrosis demonstrating non-cirrhotic status at screening Participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of the study intervention or longer if required by local regulations Exclusion Criteria: Pregnant or lactating persons Known co-infection with any of the following: HIV, Hepatitis C virus, OR Hepatitis D virus Changes in HBeAg status within 3 months prior to the screening visit Known HBV genotype A Gilbert's syndrome Any known pre-existing medical or psychiatric condition that could interfere with the participant's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to: Immunologically-mediated disease, e.g. inflammatory bowel disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, scleroderma, or sarcoidosis within 5 years of the screening visit. Current or history of any clinically significant cardiac abnormalities/dysfunction, e.g. congestive heart failure, myocardial infarction ≤6 months prior to the screening visit, pulmonary hypertension, complex congenital heart disease, significant arrhythmia, or active cardiac ischemia. Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding esophageal varices, hepatorenal syndrome, or hepatic encephalopathy. Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia Evidence of active or suspected malignancy, or a history of malignancy ≤3 years prior to the screening visit (except adequately treated carcinoma in situ, basal cell carcinoma of the skin, or stage 0 HCC that has been treated). NOTE: Participants under evaluation for malignancy are not eligible Receiving or planning to receive systemic immunosuppressive medications during the study or ≤ 2 months prior to Day1, including but not limited to prednisone >10 mg/day (or equivalent), methotrexate, cyclosporine, or interferon. NOTE: Local steroid therapy is allowed (eg, inhaled, otic, ophthalmic, or intra-articular medications) Use of any live vaccines against infectious diseases within 4 weeks of the first planned administration of study intervention or use of any non-live vaccines against infectious diseases within 2 weeks of the first planned administration of study intervention. Treatment with any investigational drug or enrollment in any other clinical study ≤ 3 months prior to Day1, or at any time during participation in the study. Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the screening visit, except for those participants monitored in an opioid substitution maintenance program.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Lead
Phone
844-466-8661
Email
clinicaltrials@immunocore.com
Facility Information:
Facility Name
University of Southern California Keck School of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University Hospitals Cleveland Medical Center Case Western Reserve
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Linear Clinical Research
City
Crawley
ZIP/Postal Code
6009
Country
Australia
Individual Site Status
Completed
Facility Name
St. Vincent's Hospital
City
Fitzroy
ZIP/Postal Code
3065
Country
Australia
Individual Site Status
Recruiting
Facility Name
Scienta Clinical Research
City
Randwick
ZIP/Postal Code
2031
Country
Australia
Individual Site Status
Completed
Facility Name
Universitair Ziekenhuis Antwerp
City
Antwerpen
ZIP/Postal Code
2060
Country
Belgium
Individual Site Status
Completed
Facility Name
Aarhus University
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Name
Queen Mary Hospital
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Pusan National University Hospital
City
Busan
ZIP/Postal Code
49241
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Gangnam Severance Hospital-Yonsei University Health System
City
Seoul
ZIP/Postal Code
06273
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
SMG-SNU Boramae Medical Center
City
Seoul
ZIP/Postal Code
07061
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Auckland Clinical Studies
City
Grafton
ZIP/Postal Code
1010
Country
New Zealand
Individual Site Status
Completed
Facility Name
ID Clinic Myslowice
City
Mysłowice
ZIP/Postal Code
41-400
Country
Poland
Individual Site Status
Completed
Facility Name
ARENSIA Exploratory Medicine Research Clinic
City
Bucharest
ZIP/Postal Code
010458
Country
Romania
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Vall d'Hebron de Barcelona
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Ramón and Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Puerta de Hierro Majadahonda
City
Majadahonda
ZIP/Postal Code
28222
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitario Virgen de la Victoria
City
Málaga
ZIP/Postal Code
29071
Country
Spain
Individual Site Status
Completed
Facility Name
Kaohsiung Medical University Chung-Ho
City
Kaohsiung City
ZIP/Postal Code
80756
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Taipei Veterans General Hospital
City
Taipei city
ZIP/Postal Code
112
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Guy's Hospital, Dept. of Infectious Disease
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Chelsea and Westminster Hospital, Research and Development, Clinical Trials Facility
City
London
ZIP/Postal Code
SW10 9NH
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Nottingham University Hospitals NHS Trust Biomedical Research Centre
City
Nottingham
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

We'll reach out to this number within 24 hrs